Skip to main content
Evidence Snapshot

Prostaglandin G/H synthase 2

CHEMBL4321 SINGLE PROTEIN Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4321
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin G/H synthase 2 as ChEMBL target CHEMBL4321, mapped to UniProt Q05769. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin G/H synthase 2
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
ChEMBL target ID
CHEMBL4321
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q05769
Prostaglandin G/H synthase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prostaglandin G/H synthase 2 matters

As of 2026-09-13

Prostaglandin G/H synthase 2 is reviewed as Prostaglandin G/H synthase 2 (UniProt Q05769); the current evidence base includes 10 approved drugs, 1209 compounds, and 193 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 1209 compounds, and 193 assays for this target. The dominant activity type is IC50. CHEMBL499069 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL499069 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prostaglandin G/H synthase 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q05769, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1209
Total Compounds
193
Total Assays
10
Approved Drugs
IC50: 1238.0, KI: 52.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL499069
10.7 IC50
No preferred name
CHEMBL525247
10.7 IC50
No preferred name
CHEMBL501208
10.7 IC50
No preferred name
CHEMBL502555
10.2 IC50
No preferred name
CHEMBL500936
10.1 IC50

Approved Drugs

Structure Compound First Approval
LUMIRACOXIB
CHEMBL404108
2005
MELOXICAM
CHEMBL599
2000
ROFECOXIB
CHEMBL122
1999
CELECOXIB
CHEMBL118
1998
DICLOFENAC
CHEMBL139
1988
FLURBIPROFEN
CHEMBL563
1986
1980
IBUPROFEN
CHEMBL521
1974
1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4321